Volpara Health Technologies Limited
Informe acción ASX:VHT
Capitalización de mercado: AU$291.3m
This company listing is no longer active This company may still be operating, however this listing is no longer active. Find out why through their latest events.
See Latest Events Volpara Health Technologies Crecimiento futuro
Future controles de criterios 1/6 Se prevé un crecimiento anual de los beneficios y los ingresos de Volpara Health Technologies de 77.3% y 17.4% por año respectivamente. Se prevé que el BPA crezca en un 77.8% al año. Se espera que la rentabilidad financiera sea de -0.2% en 3 años.
Información clave
77.3%
Tasa de crecimiento de los beneficios
77.8%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Healthcare Services 20.9% Tasa de crecimiento de los ingresos 17.4% Rentabilidad financiera futura -0.2% Cobertura de analistas Low
Última actualización 03 May 2024
Actualizaciones recientes sobre el crecimiento futuro
Price target decreased by 7.7% to AU$0.92 May 03
Price target decreased by 13% to AU$1.00 Mar 26
Price target increased by 14% to AU$1.15 Dec 15
Price target decreased by 16% to AU$1.01 Nov 22
Forecast breakeven date pushed back to 2026 Nov 22
Consensus EPS estimates fall by 137%, revenue upgraded May 25
Mostrar todas las actualizaciones Volpara Health Technologies Limited Appoints Craig Hadfield Joins as Chief Financial Officer
Price target decreased by 7.7% to AU$0.92 May 03
Volpara Health Technologies Limited Launches MQSA Compliance Software at the Society for Breast Imaging Symposium Apr 11
Price target decreased by 13% to AU$1.00 Mar 26
What Volpara Health Technologies Limited's (ASX:VHT) 52% Share Price Gain Is Not Telling You Dec 19 Lunit Inc. (KOSDAQ:A328130) agreed to acquire Volpara Health Technologies Limited (ASX:VHT) from Harbour Asset Management Limited and others for AUD300 million. Dec 15
Price target increased by 14% to AU$1.15 Dec 15
First half 2024 earnings released: NZ$0.017 loss per share (vs NZ$0.021 loss in 1H 2023) Nov 23
Price target decreased by 16% to AU$1.01 Nov 22
Forecast breakeven date pushed back to 2026 Nov 22
New major risk - Revenue and earnings growth Oct 18
Volpara Health Technologies Limited to Report Q2, 2024 Results on Oct 17, 2023 Oct 10
An Unknown buyer acquired 4% stake in Reveal DX fromVolpara Health Technologies Limited (ASX:VHT). Aug 29
Volpara Health Technologies Limited, Annual General Meeting, Aug 17, 2023 Jul 24
Volpara Health Technologies Limited to Report Q1, 2024 Results on Jul 21, 2023 Jul 12
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 26
Consensus EPS estimates fall by 137%, revenue upgraded May 25
We're Hopeful That Volpara Health Technologies (ASX:VHT) Will Use Its Cash Wisely Mar 06
Volpara Health Technologies Limited Appoints Mark Bouw as Independent, Non-Executive Director Jan 03
Forecast breakeven date pushed back to 2025 Dec 29
First half 2023 earnings released: NZ$0.02 loss per share (vs NZ$0.034 loss in 1H 2022) Nov 23
Volpara Health Technologies Limited Provides Revenue Guidance for the Full Year 2023 Nov 23
Forecast breakeven date moved forward to 2024 Nov 16
Consensus estimates of losses per share improve by 14% Oct 28
Forecast breakeven date moved forward to 2024 Oct 28
Volpara Health Technologies Limited Appoints Fred Struve as Joint Company Secretary Oct 21
Forecast to breakeven in 2025 Oct 18
Volpara Health Technologies Limited Announces the Appointment of Teri Thomas as Managing Director Oct 03
Volpara Health Launches Professional Services to Accelerate Success for High-Risk Cancer Programs Sep 21
Forecast breakeven date pushed back to 2025 Jul 29
Key Executive recently bought AU$67k worth of stock Jun 18
Now 23% undervalued after recent price drop Jun 02
Price target decreased to AU$1.15 May 31
Forecast breakeven date pushed back to 2025 May 27
Forecast breakeven date pushed back to 2025 May 26 Volpara Health Announces Chief Executive Officer Changes
No longer forecast to breakeven Apr 19
Price target decreased to AU$1.62 Feb 02
No longer forecast to breakeven Jan 20
First half 2022 earnings: EPS and revenues exceed analyst expectations Nov 24
No longer forecast to breakeven Nov 24
Price target increased to AU$2.00 Oct 26
Non-Executive Director Monica Saini has left the company Aug 19
Price target decreased to AU$1.74 Jul 27
Volpara Grows Patent Collection with Recently Granted European Protection of Image Quantification Jul 15
Insider recently sold AU$122k worth of stock Jun 16
Calculating The Intrinsic Value Of Volpara Health Technologies Limited (ASX:VHT) Jun 03
Consensus EPS estimates fall to -NZ$0.046 Jun 02
Forecast breakeven pushed back to 2024 May 29
Full year 2021 earnings released: NZ$0.07 loss per share (vs NZ$0.097 loss in FY 2020) May 29
Price target decreased to AU$1.84 May 28
Price target increased to AU$1.99 Mar 31
Does Volpara Health Technologies (ASX:VHT) Have A Healthy Balance Sheet? Mar 24
Volpara Health Technologies Signs Highest Value Contract to Date Via CRA Health Mar 13
New 90-day low: AU$1.30 Mar 03
Volpara Health Technologies Limited (ASX:VHT) acquired CRA Health Services, Inc. for $22 million. Feb 02
Price target raised to AU$1.81 Feb 02
New 90-day high: AU$1.54 Feb 02
Volpara Health Technologies (ASX:VHT) Shareholders Booked A 93% Gain In The Last Three Years Jan 28
Volpara Health Technologies Limited to Report Q3, 2021 Results on Jan 28, 2021 Jan 19
Volpara Health Technologies (ASX:VHT) Is Using Debt Safely Dec 24
Volpara Health Technologies Advises Major Customer Contract It Renewed and Extended in Second Quarter of Fiscal 2021 Is with the US Radiology Group Dec 19
First half 2021 earnings released: NZ$0.036 loss per share Nov 26
Here's What We Think About Volpara Health Technologies' (ASX:VHT) CEO Pay Nov 19 Volpara Health Technologies Announces the Launch of BreastED
New 90-day high: AU$1.47 Oct 13
New 90-day low: AU$1.27 Sep 24
Volpara Health Technologies Limited to Report Q1, 2021 Results on Jul 28, 2020 Jul 21
Previsiones de crecimiento de beneficios e ingresos ASX:VHT - Estimaciones futuras de los analistas y datos financieros pasados (NZD Millions) Fecha Ingresos Beneficios Flujo de caja libre Flujo de caja operativo Núm. de analistas medio 3/31/2026 59 2 9 12 1 3/31/2025 56 -4 3 6 2 3/31/2024 47 -7 0 3 2 9/30/2023 38 -9 1 3 N/A 6/30/2023 36 -9 -3 0 N/A 3/31/2023 35 -10 -6 -4 N/A 12/31/2022 33 -12 -10 -8 N/A 9/30/2022 31 -13 -14 -12 N/A 6/30/2022 28 -15 -14 -12 N/A 3/31/2022 26 -16 -14 -11 N/A 12/31/2021 24 -17 -14 -12 N/A 9/30/2021 23 -17 -13 -12 N/A 6/30/2021 21 -17 -14 -13 N/A 3/31/2021 20 -17 -15 -14 N/A 12/31/2020 17 -19 -16 -15 N/A 9/30/2020 15 -21 -18 -17 N/A 6/30/2020 14 -21 -18 -17 N/A 3/31/2020 13 -20 -18 -17 N/A 12/31/2019 11 -18 -16 -15 N/A 9/30/2019 10 -15 -14 -13 N/A 6/30/2019 7 -13 -13 -12 N/A 3/31/2019 5 -12 -11 -11 N/A 12/31/2018 4 -11 -11 -10 N/A 9/30/2018 4 -10 -10 -10 N/A 6/30/2018 3 -9 -9 -9 N/A 3/31/2018 3 -9 -8 -8 N/A 12/31/2017 2 -9 -8 -8 N/A 9/30/2017 2 -9 -8 -8 N/A 6/30/2017 2 -9 N/A -8 N/A 3/31/2017 2 -10 N/A -8 N/A 12/31/2016 2 -34 N/A N/A N/A 9/30/2016 3 -33 N/A -6 N/A 6/30/2016 3 -32 N/A -5 N/A 3/31/2016 3 -30 N/A -3 N/A 3/31/2015 2 -3 N/A -2 N/A 3/31/2014 1 -3 N/A N/A N/A
Mostrar más
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que VHT siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que VHT siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que VHT siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (17.4% al año) de VHT crezcan más rápidamente que los del mercado Australian (5.7% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 17.4% al año) de VHT crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: VHT se prevé que no sea rentable en 3 años.
Descubre empresas en crecimiento Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
